Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
18.60
-1.49 (-7.42%)
At close: Apr 28, 2026, 4:00 PM EDT
18.25
-0.35 (-1.88%)
After-hours: Apr 28, 2026, 4:20 PM EDT

Aktis Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Revenue
6.51.49--
Revenue Growth (YoY)
336.92%---
Cost of Revenue
67.4540.9525.92-
Gross Profit
-60.95-39.47-25.92-
Selling, General & Admin
13.7312.588.885.46
Research & Development
---14.3
Operating Expenses
13.7312.588.8819.76
Operating Income
-74.68-52.05-34.79-19.76
Interest & Investment Income
11.018.15.381.65
Other Non Operating Income (Expenses)
-0.06-0.030.780.19
Pretax Income
-63.73-43.98-28.64-17.93
Net Income
-63.73-43.98-28.64-17.93
Net Income to Common
-63.73-43.98-28.64-17.93
Shares Outstanding (Basic)
1111
Shares Outstanding (Diluted)
1111
Shares Change (YoY)
15.53%14.46%18.90%-
EPS (Basic)
-78.34-62.46-46.55-34.65
EPS (Diluted)
-78.34-62.46-46.55-34.65
Free Cash Flow
-73.7111.9-33.77-20.43
Free Cash Flow Per Share
-90.6116.90-54.89-39.49
Operating Margin
-1149.52%-3500.34%--
Profit Margin
-980.93%-2957.63%--
Free Cash Flow Margin
-1134.54%800.27%--
EBITDA
-72.36-50.48-33.67-19.32
D&A For EBITDA
2.331.581.120.45
EBIT
-74.68-52.05-34.79-19.76
Source: S&P Capital IQ. Standard template. Financial Sources.